SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Corbus Pharmaceuticals: Q1 Earnings Insights

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell 1.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.43), which missed the estimate of ($0.40).

Benzinga · 05/11/2020 12:46

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell 1.3% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were flat 0.00% year over year to ($0.43), which missed the estimate of ($0.40).

Revenue of $1,762,000 lower by 6.57% from the same period last year, which missed the estimate of $2,410,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 11, 2020

Time: 08:00 PM ET

Webcast URL: https://78449.themediaframe.com/dataconf/productusers/crbp/mediaframe/37399/indexl.html

Price Action

Company's 52-week high was at $7.99

Company's 52-week low was at $3.29

Price action over last quarter: Up 62.16%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.